
CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula (I):



(I)

or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein:

X^1 is CR^{5a} or N;

X^2 is CR^{5b} or N;

X^3 is CR^{5c} or N;

X^4 is CR^{5d} or N; provided that zero, 1, or 2 of X^1, X^2, X^3, and X^4 are N;

Z^1 and Z^2 are independently CH_2 or O; provided that at least one of Z^1 and Z^2 is CH_2;

a is zero or 1;

b is zero, 1, or 2;

d is zero, 1, or 2; provided that Z^1 and Z^2 are each CH_2 when a, b, and d are each zero;

Q is phenyl substituted with zero to 1 R^1;

A is oxadiazolyl or pyridinyl substituted with R^{4a};

R^2 is:

(i) $C_{1–4}$ alkyl, $C_{1–5}$ alkoxy, or $–NH(C_{1–6}$ alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R^{2a}; or

(ii) $C_{3–5}$ cycloalkyl substituted with zero to 3 R^{2b};

each R^1 is independently hydrogen, halo, cyano, hydroxyl, oxo, $C_{1–6}$ alkyl, $C_{2–6}$ alkenyl, $C_{2–6}$ alkynyl, $C_{1–6}$ alkoxy, $–NH_2$, $–NH(C_{1–6}$ alkyl), $–N(C_{1–6}$ alkyl)$_2$, $–C(O)(C_{1–6}$ alkyl), $–C(O)(C_{3–6}$ cycloalkyl), $–NR^xC(O)R^y$, $–C(O)OR^x$, $–C(O)NR^wR^w$, $–S(O)_2(C_{1–6}$ alkyl), $–S(O)_2(C_{3–6}$ cycloalkyl), $–NR^xS(O)_2(C_{1–6}$ alkyl), $–NR^xS(O)_2(C_{3–6}$ cycloalkyl), $–S(O)_2NR^zR^z$, $–P(O)R^yR^y$, $–(CH_2)_{0–3}(C_{3–6}$ carbocyclyl), $–O(C_{3–6}$ cycloalkyl), $–O(4-$ to 6-membered heterocyclyl), $–(CH_2)_{0–3}(4-$ to 6-membered heterocyclyl), or $–(CH_2)_{0–3}(5-$

or 6-membered heteroaryl), wherein each of said alkyl, alkoxy, alkenyl, and alkynyl is substituted with zero to 4 R^{1a} and each of said cycloalkyl, heterocyclyl, and heteroaryl is substituted with zero to 4 R^{1b};

each R^{1a} is independently halo, hydroxyl, $-NR^wR^w$, oxo, cyano, C_{1-3} alkoxy, C_{1-3} haloalkoxy, $-C(O)OR^x$, $-C(O)NR^wR^w$, or $-NR^xC(O)R^y$;

each R^{1b} is independently halo, oxo, cyano, hydroxyl, $-NH_2$, C_{1-6} alkyl, C_{1-6} alkoxy, $-NH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl)$_2$, or $-NR^xC(O)(C_{1-6}$ alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 6 R^{1a};

each R^{2a} is independently halo, cyano, hydroxyl, oxo, C_{1-3} haloalkyl, C_{1-3} alkoxy, C_{1-3} haloalkoxy, $-NR^xR^x$, $-C(O)(C_{1-6}$ alkyl), $-C(O)(C_{3-6}$ cycloalkyl), $-NR^xC(O)R^y$, $-C(O)(C_{1-6}$ alkyl), $-C(O)OR^x$, $-C(O)NR^wR^w$, $-S(O)_2R^y$, $-S(O)_2(C_{1-3}$ fluoroalkyl), $-NR^xS(O)_2(C_{1-3}$ alkyl), $-NR^xS(O)_2(C_{3-6}$ cycloalkyl), $-S(O)_2NR^zR^z$, or $-P(O)R^yR^y$;

each R^{2b} is independently halo, cyano, hydroxyl, oxo, C_{1-6} alkyl, C_{1-6} alkoxy, $-NR^xR^x$, $-NR^xC(O)O(C_{1-4}$ alkyl), $-C(O)(C_{1-3}$ alkyl), or $-S(O)_2(C_{1-3}$ alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 6 R^{2a};

R^{3a} and R^{3b} are independently hydrogen, C_{1-3} alkyl, C_{1-3} haloalkyl, or C_{3-6} cycloalkyl, or R^{3a} and R^{3b}, taken together with the carbon atom to which they are attached, form a C_{3-6} cycloalkyl;

R^{4a} is halo, cyano, hydroxyl, $-NH_2$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, $-(CH_2)_{0-3}NH(C_{1-6}$ alkyl), $-(CH_2)_{0-2}N(C_{1-6}$ alkyl)$_2$, $-(CH_2)_{0-3}(C_{3-6}$ cycloalkyl), or $-(CH_2)_{0-3}$(4- to 6-membered heterocyclyl), wherein each of said alkyl, alkoxy, alkenyl, and alkynyl is substituted with zero to 6 R^{4d} and each of said cycloalkyl and heterocyclyl is substituted with zero to 3 R^{4e};

each R^{4d} is independently halo, hydroxyl, $-NR^xR^x$, oxo, cyano, C_{1-3} alkoxy, or C_{1-3} haloalkoxy;

each R^{4e} is independently halo, oxo, cyano, hydroxyl, $-NH_2$, C_{1-6} alkyl, C_{1-6} alkoxy, $-NH(C_{1-6}$ alkyl), or $-N(C_{1-6}$ alkyl)$_2$, wherein each of said alkyl and alkoxy is substituted with zero to 6 R^{4d};

each of R^{5a}, R^{5b}, R^{5c}, and R^{5d} is independently hydrogen, halo, hydroxy, cyano, C_{1-6} alkyl substituted with zero to 6 R^{5e}, C_{1-6} alkoxy substituted with zero to 6 R^{5e}, $-C(O)OR^x$, $-C(O)NR^wR^w$, $-S(O)_2R^y$, $-S(O)_2NR^zR^z$, or phenyl substituted with zero to 3 R^{5f};

each of R^{5e} is independently halo, hydroxyl, $-NR^xR^x$, oxo, cyano, C_{1-3} alkoxy, or C_{1-3}

haloalkoxy;

each R^{5f} is independently halo, oxo, cyano, hydroxyl, $-NH_2$, C_{1-6} alkyl, C_{1-6} alkoxy, $-NH(C_{1-6}$ alkyl), or $-N(C_{1-6}$ alkyl$)_2$, wherein each of said alkyl and alkoxy is substituted with zero to 6 R^{5e};

each R^w is independently hydrogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or alternatively, two R^w, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S;

each R^x is independently hydrogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

each R^y is independently C_{1-6} alkyl or C_{3-6} cycloalkyl; and

each R^z is independently hydrogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or alternatively, two R^z, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S.

2. The compound according to claim 1 or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein:

each R^1 is independently F, Cl, Br, cyano, hydroxyl, oxo, $-NH_2$, C_{1-5} alkyl, C_{1-4} alkoxy, $-NR^x(C_{1-4}$ alkyl), $-NR^xC(O)R^y$, $-C(O)(C_{1-4}$ alkyl), $-C(O)OR^x$, $-C(O)NR^wR^w$, $-S(O)_2(C_{1-4}$ alkyl), $-S(O)_2(C_{3-6}$ cycloalkyl), $-NR^xS(O)_2(C_{1-4}$ alkyl), $-NR^xS(O)_2(C_{3-6}$ cycloalkyl), $-S(O)_2NR^zR^z$, $-P(O)R^yR^y$, $-(CH_2)_{0-3}(C_{3-6}$ carbocyclyl), $-O(C_{3-6}$ cycloalkyl), $-O(4-$ to 6-membered heterocyclyl), $-(CH_2)_{0-3}(4-$ to 6-membered heterocyclyl), or $-(CH_2)_{0-3}(5-$ or 6-membered heteroaryl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R^{1a} and each of said cycloalkyl, heterocyclyl, and heteroaryl is substituted with zero to 3 R^{1b};

each R^{1a} is independently F, Cl, hydroxyl, $-NR^wR^w$, oxo, cyano, C_{1-3} alkoxy, C_{1-3} haloalkoxy, or $-C(O)OH$;

each R^{1b} is independently F, Cl, cyano, hydroxyl, oxo, $-NH_2$, C_{1-4} alkyl, C_{1-4} alkoxy, $-NH(C_{1-4}$ alkyl), $-N(C_{1-4}$ alkyl$)_2$, or $-NR^xC(O)$ (C_{1-6} alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 6 R^{1a};

each R^{2a} is independently F, Cl, hydroxyl, $-NR^xR^x$, oxo, cyano, C_{1-3} alkoxy, C_{1-3} haloalkoxy, or $-C(O)OH$;

R^{4a} is F, Cl, cyano, hydroxyl, $-NH_2$, C_{1-4} alkyl, C_{1-4} alkoxy, $-(CH_2)_{0-3}NH(C_{1-6}$ alkyl), $-(CH_2)_{0-3}N(C_{1-6}$ alkyl$)_2$, $-(CH_2)_{0-3}(C_{3-6}$ cycloalkyl), or $-(CH_2)_{0-3}$(4- to 6-membered heterocyclyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R^{4d}; and each of said cycloalkyl and heterocyclyl is substituted with zero to 3 R^{4e};

each R^{4c} is independently hydrogen, C_{1-3} alkyl, or C_{3-6} cycloalkyl;

each R^{4d} is independently F, Cl, hydroxyl, $-NR^xR^x$, oxo, cyano, C_{1-3} alkoxy, or C_{1-3} fluoroalkoxy;

each R^{4e} is independently F, Cl, oxo, cyano, hydroxyl, $-NH_2$, C_{1-4} alkyl, C_{1-4} alkoxy, or $-NH(C_{1-6}$ alkyl), or $-N(C_{1-6}$ alkyl$)_2$, wherein each of said alkyl and alkoxy is substituted with zero to 4 R^{4d};

each of R^{5a}, R^{5b}, R^{5c}, and R^{5d} is independently hydrogen, F, Cl, hydroxy, cyano, C_{1-3} alkyl substituted with zero to 4 R^{5e}, C_{1-3} alkoxy substituted with zero to 4 R^{5e}, $-C(O)OR^x$, $-C(O)NR^wR^w$, $-S(O)_2R^y$, $-S(O)_2NR^zR^z$, or phenyl substituted with zero to 3 R^{5f};

each R^w is independently hydrogen, C_{1-4} alkyl, or C_{3-6} cycloalkyl; or alternatively, two R^w, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S;

each R^x is independently H, C_{1-4} alkyl, or C_{3-6} cycloalkyl;

R^y is C_{1-4} alkyl or C_{3-6} cycloalkyl; and

each R^z is independently hydrogen, C_{1-4} alkyl, or C_{3-6} cycloalkyl; or alternatively, two R^z, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S.

3. The compound according to any one of claims 1-2 or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein:

X^1 is CR^{5a};

X^2 is CR^{5b} or N;

X^3 is CR^{5c} or N;

X^4 is CR^{5d} or N; provided that zero, 1, or 2 of X^2, X^3, and X^4 is N;

Z^1 and Z^2 are independently CH_2 or O; provided that at least one of Z^1 and Z^2 is CH_2;

a is 1;

b is 1;

d is 1;

each R^1 is independently hydrogen, F, Cl, Br, cyano, hydroxyl, oxo, $C_{1–4}$ alkyl, $C_{1–2}$ fluoroalkyl, $–CH_2Cl$, $C_{1–4}$ hydroxyalkyl, $–C(CH_3)_2CN$, $–CH(OH)CHF_2$, $–CH_2OCH_3$, $C_{1–4}$ alkoxy, $C_{1–2}$ fluoroalkoxy, $–OCF_2Cl$, $–OC(CH_3)_2CN$, $–C(CH_3)_2OCHF_2$, $–OC(CH_3)_2C(O)NH_2$, –C(O)OH, $–C(O)O(C_{1-2}$ alkyl), $–C(O)NH_2$, –O(cyclopropyl), $–CH_2$(cyclopropyl), $–CH_2$(oxetanyl), $–NHC(O)CH_3$, $–NHS(O)_2CH_3$, $–NHS(O)_2CH(CH_3)_2$, $–NHS(O)_2CF_3$, $–NHS(O)_2$(cyclopropyl), $–S(O)_2CH_3$, $–S(O)_2$(cyclopropyl), $–S(O)_2NH_2$, cyclopropyl, acetamidocyclopropyl, cyanocyclopropyl, difluorocyclobutyl, hydroxycyclopropyl, methoxycyclopropyl, cyclohexenyl, dihydropyranyl, oxetanyl, methyloxetanyl, tetrahydropyranyl, aminooxadiazolyl, pyridinyl, or fluorobicyclo[1.1.1]pentyl;

each R^{2a} is independently F, cyano, hydroxyl, $C_{1–2}$ alkoxy, or $–NR^xR^x$;

each R^{2b} is independently F, cyano, hydroxyl, $C_{1–3}$ alkyl, $C_{1–2}$ fluoroalkyl, $C_{1–3}$ hydroxyalkyl, $C_{1–2}$ alkoxy, C_{1-2} fluoroalkoxy, $–NR^xR^x$, $–NR^xC(O)O(C_{1–4}$ alkyl), $–C(O)(C_{1–2}$ alkyl), $–C(O)(C_{1–2}$ fluoroalkyl), or $–S(O)_2(C_{1–2}$ alkyl);

one of R^{3a} and R^{3b} is hydrogen and the other of R^{3a} and R^{3b} is hydrogen or $–CH_3$;

R^{4a} is cyano, $–CH_3$, $–CH(CH_3)_2$, $–C(CH_3)_3$, $–CHF_2$, $–CF_3$, $–CF_2CH_3$, $–C(CH_3)_2F$, $–C(CH_3)_2OH$, $–C(CH_3)_2CN$, $–OCH_3$, $–C(O)N(CH_3)_2$, $–CH_2$(cyclopropyl), cyclopropyl, fluorocyclopropyl, methylcyclopropyl, cyanocyclopropyl, trifluoromethylcyclopropyl, difluorocyclopropyl, methyloxetanyl, tetrahydropyranyl, or fluorobicyclo[1.1.1]pentyl; and

each of R^{5a}, R^{5b}, R^{5c}, and R^{5d} is hydrogen.

4. The compound according to any one of claims 1-2 or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein:

X^1 is CH;

X^2 is CH or N;

X^3 is CH or N;

X^4 is CH; provided that zero or 1 or X^2 and X^3 are N;

Z^1 and Z^2 are independently CH_2 or O; provided that at least one of Z^1 and Z^2 is CH_2;

a is 1;

b is 1;


d is 1;

each R^1 is independently C_{1-4} alkyl, $-CHF_2$, $-CF_3$, $-CH_2CF_3$, $-CF_2CH_3$, $-CH_2CHF_2$, $-C(CH_3)_2OH$, $-CH_2OCH_3$, $-C(CH_3)_2OCH_3$, $-OCH_3$, $-OCH_2CH_3$, $-OC(CH_3)_2CN$, $-C(CH_3)_2OCHF_2$, $-C(O)OCH_3$, $-C(O)OCH_2CH_3$, $-CH_2$(cyclopropyl), $-S(O)_2CH_3$, $-S(O)_2$(cyclopropyl), =O, difluorocyclobutyl, fluorobicyclo[1.1.1]pentyl, oxetanyl, methyl oxetanyl, pyridinyl tetrahydropyranyl, or cyclopropyl substituted with zero to 1 substituent selected from hydroxyl, $-CH_3$, $-OCH_3$, and $-NHC(O)CH_3$;

R^{3a} is hydrogen or $-CH_3$; and


R^{3b} is hydrogen.

5. The compound according to any one of claims 1-2 or a stereoisomer, a tautomer, or a salt or solvate thereof, having the structure:




.

6. The compound according to any one of claims 1-2 or a stereoisomer or a salt thereof, having the structure:




.

7. The compound according to any one of claims 1-2 or a stereoisomer or a salt thereof, having the structure:



.

8. The compound according to any one of claims 1-2 or a stereoisomer, a tautomer, or a salt or solvate thereof, having the structure:




.

9. The compound according to any one of claims 1-2 or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein:


A is pyridinyl substituted with R^{4a}.

10. The compound according to any one of claims 1-2 or a stereoisomer or a salt thereof, having the structure:



.

11. The compound according to any one of claims 1-2 or a stereoisomer or a salt thereof, having the structure:



.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any one of claims 1 to 11 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof.

13. A compound according to any one of claims 1 to 11 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy.

14. A compound according to any one of claims 1 to 11 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, for use in treating pathological fibrosis, cancer, inflammatory disorders, metabolic, or cholestatic disorders.

15. The compound for use according to claim 14, wherein the pathological fibrosis is liver fibrosis, renal fibrosis, biliary fibrosis, or pancreatic fibrosis.

16. A compound according to any one of claims 1 to 11 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, for use in treating nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC), or primary biliary cirrhosis (PBC).

17. A compound according to any one of claims 1 to 11 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, for use in treating idiopathic pulmonary fibrosis (IPF).